MannKind is trading 5.32% down at $3.65, with no clear company-specific announcement dated August 13, 2026, explaining the decline.

  • The latest identified corporate release was the August 5 second-quarter update.
  • It highlighted 43% revenue growth, Furoscix ReadyFlow approval, and other milestones, alongside investor caution around rising expenses.
  • Broader markets are higher, so macro sentiment does not explain the drop.